Please wait while we load the requested 10-Q report or click the link below:
NPS Pharmaceuticals Reports Second Quarter 2013 Financial Results and Provides Business Update
-- U.S. launch of Gattex® (teduglutide) accelerating with net product sales of $4.8 million in quarter --
-- $25 to $30 million in full-year net global Gattex® sales expected with 275 to 325 patients on therapy by year end --
-- Ex-U.S. markets expected to double global peak sales opportunity for Gattex®/Revestive® --
-- Natpara fill-finish manufacturing issue successfully addressed and submission of Biologic License Application expected in fourth quarter --
-- Conference call today at 5:00 PM ET –-
BEDMINSTER, N.J.--(BUSINESS WIRE)--August 8, 2013--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, reported its results for the second quarter ended June 30, 2013.
“Having successfully addressed the fill-finish issue, we are pleased to report that we will file our Biologic License Application for Natpara before the end of this year,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “Our commitment to flawless execution has yielded solid second quarter results including Gattex sales that exceeded our own expectations. We are particularly gratified to have already brought this life-changing treatment to 141 Short Bowel Syndrome patients and I am pleased to report that we are increasing our guidance to 275 to 325 patients on therapy by the end of the year.”
The following information was filed by Nps Pharmaceuticals Inc (NPSP) on Thursday, August 8, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Nps Pharmaceuticals Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Nps Pharmaceuticals Inc.